Avistone Biotechnology Co. Ltd. has recently gained conditional approval from the National Medical Products Administration (NMPA) to market Vebreltinib, a precision oncology therapeutic, for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. This approval is based on encouraging results from the Phase II KUNPENG study, revealing a 75.0% objective response rate (ORR) and a median progression-free survival (PFS) of 14.1 months in patients with advanced METex14 mutations. These results were presented at the 2023 European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain (Poster# 1379P), demonstrating a favorable safety profile.

MET signaling plays a crucial role in cell proliferation, migration, invasion, and survival, and genomic alterations in MET can lead to oncogenesis, including MET exon 14 skipping (METex14). METex14 is an independent prognostic factor associated with poorer survival rates in NSCLC patients.

Avistone, expressed optimism about providing a new treatment option to patients with MET exon 14 skipping NSCLC in China, acknowledging the historical challenges in developing drugs targeting MET indications. Avistone holds exclusive rights to Vebreltinib in China, Hong Kong, and Macau.

Source: businesswire.com